Prof. Dr. Joop van den Bergh

1. • Highlights ASBMR 2021 – San Diego
Copyright
Prof. Dr. Joop van den Bergh

2. • Highlights ASBMR 2021 – San Diego
X
Copyright
Prof. Dr. Joop van den Bergh

3. Copyright
Prof. Dr. Joop van den Bergh

4. Relations that could be relevant for the meeting Company name
•
• Research funds
• Speaker board / consultancy
• Stakeholder
• Stock or other…
•
• Amgen, UCB, Eli Lilly
• Amgen, UCB
• -
• -
Disclosures
Copyright
Prof. Dr. Joop van den Bergh

5. Fracture risk
Copyright
Prof. Dr. Joop van den Bergh

6. Copyright
Prof. Dr. Joop van den Bergh

7. Copyright
Prof. Dr. Joop van den Bergh

8. Copyright
Prof. Dr. Joop van den Bergh

9. Copyright
Prof. Dr. Joop van den Bergh

10. Copyright
Prof. Dr. Joop van den Bergh

11. Copyright
Prof. Dr. Joop van den Bergh

12. Copyright
Prof. Dr. Joop van den Bergh

13. Copyright
Prof. Dr. Joop van den Bergh

14. Copyright
Prof. Dr. Joop van den Bergh

15. Copyright
Prof. Dr. Joop van den Bergh

16. Treatment - BMD
Copyright
Prof. Dr. Joop van den Bergh

17. Copyright
Prof. Dr. Joop van den Bergh

18. Copyright
Prof. Dr. Joop van den Bergh

19. Copyright
Prof. Dr. Joop van den Bergh

20. Total Hip BMD
∆
Copyright
Prof. Dr. Joop van den Bergh

21. Total Hip BMD
∆
Copyright
Prof. Dr. Joop van den Bergh

22. Copyright
Prof. Dr. Joop van den Bergh

23. Copyright
Prof. Dr. Joop van den Bergh

24. Copyright
Prof. Dr. Joop van den Bergh

25. Copyright
Prof. Dr. Joop van den Bergh

26. Spine
Total Hip
Copyright
Prof. Dr. Joop van den Bergh

27. Copyright
Prof. Dr. Joop van den Bergh

28. Copyright
Prof. Dr. Joop van den Bergh

29. Copyright
Prof. Dr. Joop van den Bergh

30. Copyright
Prof. Dr. Joop van den Bergh

31. Treatment – drug holiday
Copyright
Prof. Dr. Joop van den Bergh

32. ASBMR/ECTS Clinical Debate: Intermittent Drug Holidays Are
Mandatory for Long Term Bisphosphonate Treatment of
Osteoporosis?
ASBMR – in support
ECTS - against
Copyright
Prof. Dr. Joop van den Bergh

33. ASBMR/ECTS Clinical Debate: Intermittent Drug Holidays Are
Mandatory for Long Term Bisphosphonate Treatment of
Osteoporosis?
ASBMR – in support
Winner: ECTS - against
Copyright
Prof. Dr. Joop van den Bergh

34. Copyright
Prof. Dr. Joop van den Bergh

35. Copyright
Prof. Dr. Joop van den Bergh

36. Mandatory = obligatory, binding
Copyright
Prof. Dr. Joop van den Bergh

37. Treatment: new and real-world data
Copyright
Prof. Dr. Joop van den Bergh

38. A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low
Bone Mass – 6 Month Bone Mineral Density (BMD) results
Copyright
Prof. Dr. Joop van den Bergh

39. Copyright
Prof. Dr. Joop van den Bergh

40. Copyright
Prof. Dr. Joop van den Bergh

41. Copyright
Prof. Dr. Joop van den Bergh

42. Copyright
Prof. Dr. Joop van den Bergh

43. Copyright
Prof. Dr. Joop van den Bergh

44. Copyright
Prof. Dr. Joop van den Bergh

45. Teriparatide / Abaloparatide
Copyright
Prof. Dr. Joop van den Bergh

46. Copyright
Prof. Dr. Joop van den Bergh

47. Copyright
Prof. Dr. Joop van den Bergh

48. Copyright
Prof. Dr. Joop van den Bergh

49. Copyright
Prof. Dr. Joop van den Bergh

50. Copyright
Prof. Dr. Joop van den Bergh

51. Treatment – safety
Copyright
Prof. Dr. Joop van den Bergh

52. ONJ
Copyright
Prof. Dr. Joop van den Bergh

53. Copyright
Prof. Dr. Joop van den Bergh

54. Copyright
Prof. Dr. Joop van den Bergh

55. Copyright
Prof. Dr. Joop van den Bergh

56. AFF
Copyright
Prof. Dr. Joop van den Bergh

57. Copyright
Prof. Dr. Joop van den Bergh

58. • The cohort consists of 60 AFF patients (almost all treated with BPs)
• The AFF patients were classified into three groups:
• group 1, clinically suspected of a monogenic bone disorder and genetically
confirmed with a pathogenic variant through NGS gene panel testing as routine
medical care
• group 2, clinically suspected of a monogenic bone disorder without genetic
confirmation
• group 3, no clinical suspicion of monogenic bone disorders
• Whole exome sequencing (WES) was performed in all patients and
variants were classified based on the American College of Medical
Genetics and Genomics (ACMG) classification guideline
Copyright
Prof. Dr. Joop van den Bergh

59. Copyright
Prof. Dr. Joop van den Bergh

60. Copyright
Prof. Dr. Joop van den Bergh

61. Copyright
Prof. Dr. Joop van den Bergh

62. Copyright
Prof. Dr. Joop van den Bergh

63. Copyright
Prof. Dr. Joop van den Bergh

64. Copyright
Prof. Dr. Joop van den Bergh

65. Copyright
Prof. Dr. Joop van den Bergh

66. Copyright
Prof. Dr. Joop van den Bergh

67. Copyright
Prof. Dr. Joop van den Bergh

68. Copyright
Prof. Dr. Joop van den Bergh

69. Vitamin D
Copyright
Prof. Dr. Joop van den Bergh

70. Copyright
Prof. Dr. Joop van den Bergh

71. Copyright
Prof. Dr. Joop van den Bergh

72. Copyright
Prof. Dr. Joop van den Bergh

73. Copyright
Prof. Dr. Joop van den Bergh

74. Copyright
Prof. Dr. Joop van den Bergh

75. Copyright
Prof. Dr. Joop van den Bergh

76. Copyright
Prof. Dr. Joop van den Bergh

77. Copyright
Prof. Dr. Joop van den Bergh

78. Copyright
Prof. Dr. Joop van den Bergh

79. Copyright
Prof. Dr. Joop van den Bergh

80. Copyright
Prof. Dr. Joop van den Bergh

81. Copyright
Prof. Dr. Joop van den Bergh

82. Artificial Intelligence
Copyright
Prof. Dr. Joop van den Bergh

83. Copyright
Prof. Dr. Joop van den Bergh

84. Copyright
Prof. Dr. Joop van den Bergh

85. Copyright
Prof. Dr. Joop van den Bergh

86. Copyright
Prof. Dr. Joop van den Bergh

87. Copyright
Prof. Dr. Joop van den Bergh

88. Copyright
Prof. Dr. Joop van den Bergh

89. Scoliosis and spine shape
Copyright
Prof. Dr. Joop van den Bergh

90. Copyright
Prof. Dr. Joop van den Bergh

91. Copyright
Prof. Dr. Joop van den Bergh